South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral disease that infects millions of people around the world every year.
Hyundai Bio’s drug candidate Xafty is a new formulation of niclosamide, used for decades to treat infections caused by parasitic worms and in recent years proposed as a potential therapy for viral and bacterial diseases.
